Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension

Crit Care Med. 2024 Aug 1;52(8):1218-1227. doi: 10.1097/CCM.0000000000006273. Epub 2024 Mar 21.

Abstract

Objectives: The relationship between renin levels, exposure to renin-angiotensin system (RAS) inhibitors, angiotensin II (ANGII) responsiveness, and outcome in patients with vasopressor-dependent vasodilatory hypotension is unknown.

Design: We conducted a single-center prospective observational study to explore whether recent RAS inhibitor exposure affected baseline renin levels, whether baseline renin levels predicted ANGII responsiveness, and whether renin levels at 24 hours were associated with clinical outcomes.

Setting: An academic ICU in Melbourne, VIC, Australia.

Patients: Forty critically ill adults who received ANGII as the primary agent for vasopressor-dependent vasodilatory hypotension who were included in the Acute Renal effects of Angiotensin II Management in Shock study.

Interventions: None.

Measurements and main results: After multivariable adjustment, recent exposure to a RAS inhibitor was independently associated with a relative increase in baseline renin levels by 198% (95% CI, 36-552%). The peak amount of ANGII required to achieve target mean arterial pressure was independently associated with baseline renin level (increase by 46% per ten-fold increase; 95% CI, 8-98%). Higher renin levels at 24 hours after ANGII initiation were independently associated with fewer days alive and free of continuous renal replacement therapy (CRRT) (-7 d per ten-fold increase; 95% CI, -12 to -1).

Conclusions: In patients with vasopressor-dependent vasodilatory hypotension, recent RAS inhibitor exposure was associated with higher baseline renin levels. Such higher renin levels were then associated with decreased ANGII responsiveness. Higher renin levels at 24 hours despite ANGII infusion were associated with fewer days alive and CRRT-free. These preliminary findings emphasize the importance of the RAS and the role of renin as a biomarker in patients with vasopressor-dependent vasodilatory hypotension.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Angiotensin II* / blood
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Hypotension* / drug therapy
  • Male
  • Middle Aged
  • Prospective Studies
  • Renal Replacement Therapy
  • Renin* / blood
  • Renin-Angiotensin System* / drug effects
  • Renin-Angiotensin System* / physiology
  • Vasoconstrictor Agents* / therapeutic use

Substances

  • Angiotensin II
  • Renin
  • Vasoconstrictor Agents
  • Angiotensin-Converting Enzyme Inhibitors